Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Core One Labs (COOL) subsidiary Vocan Biotechnologies is finalizing its provisional patent application for biosynthetic psilocybin production
  • Vocan, operating under a Health Canada Controlled Drugs and Substances Dealer’s lab, expects to complete the application in the coming days
  • Vocan will also make a provisional application to the United States Patent and Trademark Office
  • Core One believes the production method will provide the reliability required for empirical, clinical and medical psychedelic research
  • Core One is a biotechnology enterprise focused on bringing psychedelic medicines to market
  • Core One Labs (COOL) is up by 11.86 per cent and is currently trading at $0.66 per share

Core One Labs (COOL) subsidiary Vocan Biotechnologies is finalizing its provisional patent application for biosynthetic psilocybin production.

Vocan, operating under a Health Canada Controlled Drugs and Substances Dealer’s lab, expects to complete the application in the coming days, at which time it will make a provisional application to the United States Patent and Trademark Office.

The process of extracting naturally occurring psilocybin from a host plant is inefficient and very expensive, as are synthetic processing techniques. Vocan’s provisional patent application addresses these inefficiencies and cost prohibitions.

Vocan and The University of British Columbia’s approach to producing biosynthetic psilocybin has the potential to yield a product consistent in quality and concentration, and stereochemically comparable to its naturally occurring compound.

Core One believes this collaboration will provide the reliability required for empirical, clinical and medical psychedelic research.

Joel Shacker, Core One Labs’ CEO, commented,

“Core One Labs submitting its patent for its revolutionary biosynthetic psilocybin production system is imminent as we are just days away. This could position the company as the leader in provision of pharmaceutical API-grade psilocybin which could ultimately drive value for shareholders and stakeholders alike.

We have assembled a world-class team to promote and sell our biosynthesized psilocybin to other major companies that are working on therapeutic psychedelic solutions. With current prices of psilocybin being over US$7000 per gram, we view this space as being highly profitable.”

Core One is a biotechnology enterprise focused on bringing psychedelic medicines to market.

Core One Labs (COOL) is up by 11.86 per cent and is currently trading at $0.66 per share as of 11:46 am ET.

More From The Market Herald

" Hemostemix (TSXV:HEM) announces non-brokered private placement

Hemostemix (HEM) has announced a non-brokered private placement of up to 15 million units.
WELL Health - Chairman & CEO Hamed Shahbazi

" WELL Health (TSX:WELL) closes $34.5M public offering

WELL Health Technologies Corp. (WELL) has completed a bought deal public offering for proceeds of $34.5 million.

" Simply Better Brands (TSXV:SBBC) enters the weight loss category

Simply Better Brands (SBBC) has launched its entry into the weight loss category with a PureKana Keto Gummy.

" Cardiol Therapeutics (TSX:CRDL) appoints new directors

Cardiol Therapeutics (CRDL) has appointed Teri Loxam and Chris Waddick to its Board of Directors, effective immediately.